FDA approves giredestrant for ESR1-mutated breast cancer and neladalkib for ALK lung cancer; FDA rejects ivonescimab

An infusion bag of amber fluid hanging from a single upright IV pole whose top bends into two curved hooks like a shepherd's crook, with a drip chamber, roller clamp and capped tubing below.

The Food and Drug Administration (FDA) approved giredestrant with everolimus on Nov. 16 for ESR1-mutated breast cancer, then granted accelerated approval to the ALK inhibitor neladalkib on Nov. 17 for previously treated lung cancer.

The FDA also rejected ivonescimab in EGFR-mutated lung cancer over a nonsignificant survival result and removed a central nervous system lymphoma restriction from the liso-cel label. The European Commission approved daraxonrasib for previously treated pancreatic cancer.

  • FDA Nov 16, 2026
    The Food and Drug Administration (FDA) approved giredestrant (Wilserdly, Genentech), an oral estrogen receptor antagonist, with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer that recurred or progressed on endocrine therapy, and authorized FoundationOne Liquid CDx as the companion diagnostic. In the randomized evERA trial of 373 adults, median progression-free survival in the ESR1-mutated population was 10 months versus 5.5 months with physician's choice of endocrine therapy plus everolimus (hazard ratio 0.38, 95% CI 0.27 to 0.54). Common adverse reactions included stomatitis, rash, fatigue, diarrhea and pneumonitis.
  • FDA Nov 17, 2026
    The Food and Drug Administration (FDA) granted accelerated approval to neladalkib (Nelkarmi, Nuvalent), a kinase inhibitor, for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer previously treated with alectinib or with two or more ALK inhibitors plus platinum chemotherapy. In the single-arm ALKOVE-1 trial, the overall response rate was 49% in 67 patients after alectinib and 32% in 155 patients after two or more ALK inhibitors and chemotherapy. Hepatotoxicity was among the most common adverse reactions; the recommended dose is 150 mg once daily.
    Sources: FDA, OncLive
  • FDA Nov 15, 2026
    Summit Therapeutics said the Food and Drug Administration (FDA) issued a complete response letter for ivonescimab with platinum chemotherapy in EGFR-mutated advanced non-small cell lung cancer after EGFR inhibitors, citing no statistically significant overall survival improvement. In phase 3 HARMONi, median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14 months with placebo plus chemotherapy, not significant (hazard ratio 0.79, 95% CI 0.62 to 1.01; P = .0570); median progression-free survival was 6.8 versus 4.4 months (hazard ratio 0.52). FDA reviewers said 93% of progression-free survival events were in patients enrolled in China, Fierce Pharma reported.
  • FDA Nov 17, 2026
    The Food and Drug Administration (FDA) removed the limitation of use that excluded patients with primary or secondary central nervous system (CNS) lymphoma from the label of lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb), OncLive reported Nov. 17; the change does not create a separate indication for primary CNS lymphoma. The label cites a study of five patients with relapsed or refractory primary CNS lymphoma, in which cytokine release syndrome occurred in 60%, none grade 3 or higher, and neurologic toxicities in 40%. Axicabtagene ciloleucel's label dropped the same limitation in February 2026.
  • Policy Nov 16, 2026
    The European Commission approved daraxonrasib (Rasonque) as monotherapy for adults with metastatic pancreatic adenocarcinoma previously treated with at least one systemic therapy, whether or not a RAS mutation has been detected in the tumor, OncLive reported Nov. 16. In the phase 3 RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, and median progression-free survival by blinded central review was 7.2 versus 3.6 months. Rash occurred in 85% of patients and diarrhea in 58%; the Food and Drug Administration approved the drug Aug. 26, 2026.
    Source: OncLive

The weekly innovation roundup for oncology, published every Sunday for the week before; every item links to its sources. Latest oncology news · All specialties

Latest news

Tagged oncology, from the daily briefing

  1. Phase 3 PACE-NODES trial reports early adverse events for pelvic nodal plus prostate SBRT versus prostate-only SBRT
  2. REFUEL trial tests a 12-week multidisciplinary program for persistent fatigue in lymphoma survivors
  3. ALNEO phase 2 trial reports neoadjuvant alectinib before surgery in resectable stage III ALK-positive lung cancer

See all the latest news